Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently outspent CymaBay, with its SG&A expenses peaking at approximately $336 million in 2023, a staggering 360% increase from 2014. In contrast, CymaBay's expenses grew more modestly, reaching around $52 million in 2023, marking a 535% increase from its 2014 figures. This disparity highlights the differing scales and strategies of these two companies. While Supernus's larger budget may reflect a broader market reach or more extensive operations, CymaBay's leaner approach could indicate a focus on efficiency. Understanding these trends provides valuable insights into the financial strategies of biotech firms.